TD Cowen maintains its Buy rating on Boston Scientific, signaling continued confidence in the medtech giant's growth prospectsExecutive summary: TD Cowen maintained its Buy rating on Boston Scientific (BSX) stock. The affirmation signals continued analyst confidence despite recent mixed rating actions, potentially influencing investor perception and share price stability. TD Cowen analyst team and Boston Scientific. Investors will watch for Boston Scientific's upcoming quarterly results and any further analyst rating updates or regulatory developments.TD Cowen analysts affirmed their Buy recommendation on Boston Scientific (BSX), indicating that the firm remains optimistic about the company's medical device portfolio and future growth. The affirmation comes amid a backdrop of mixed analyst actions, including recent target cuts and overlapping overweight ratings from other firms. While the rating itself does not introduce new information, it reinforces a positive stance that may help stabilise investor sentiment ahead of upcoming earnings.Connected developmentsPrevious analyst actions on Boston Scientific (BSX)Is Boston Scientific (BSX) One of the Best Healthcare Stocks to Buy With the Highest Upside Potential?Open the full case file on Beyond →
Social Pulse
AI estimate · not scraped